[Ip-health] US PTO rejects 4 tenofovir patents from Gilead
Sandeep.Rathod@matrixlabsindia.com
Sandeep.Rathod@matrixlabsindia.com
Thu Jan 24 07:32:02 2008
This is a multipart message in MIME format.
--
[ Picked text/plain from multipart/alternative ]
PUBPAT announced on Jan/23 that the U.S. Patent & Trademark Office has=0D
rejected [non-final rejections] four key HIV/AIDS drug patents held by=0D
Gilead Sciences that relate to tenofovir disoproxil fumarate (TDF). Gilead=
=0D
markets TDF in the United States under the brand name VIREAD and as a part=
=0D
of its ATRIPLA combination product.=0D
The Gilead Sciences TDF patents challenged by PUBPAT that have now been=0D
rejected by the Patent Office are U.S. Patents No. 5,922,695, 5,935,946,=0D
5,977,089 and 6,043,230.=0D
=0D
NOTE: The above 4 are the OB listed patents for Tenofovir.=0D
=0D
Such non-final rejections are not extra-ordinary for patents where=0D
re-examination has been asked for.=0D
Pfizer too has had similar problems for Atorvastatin [Lipitor (R)]=0D
patents. Gilead still has the opportunity to address the PTO=E2=80=99s reje=
ctions.=0D
DISCLAIMER=0D
(i) The information contained in this e-mail message is intended only for t=
he confidential use of the recipient(s)=0D
named above. This message is privileged and confidential. If the reader of =
this message is not the intended recipient=0D
or an agent responsible for delivering it to the intended recipient, you ar=
e hereby notified that you have received this=0D
document in error and that any review use, dissemination distribution, tran=
smission, printing, copying, alteration, or=0D
circulation of this message is strictly prohibited.=0D
(ii) The sender confirms that Matrix Laboratories Limited shall not be resp=
onsible if this email message is used for any=0D
indecent, unsolicited or illegal purposes, which is in violation of any exi=
sting laws and the same shall solely be the=0D
responsibility of the recipient and that Matrix Laboratories Limited shall =
at all times be indemnified against any civil=0D
and/ or criminal liabilities or consequences thereof by such recipient=0D
--